ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 6, 2006, Pages 682-690

  Coller, Janet K ^a   Barratt, Daniel T ^a   Dahlen, Karianne ^a   Loennechen, Morten H ^a   Somogyi, Andrew A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; METHADONE; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ADULT; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DNA ISOLATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 33845528364     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.09.011     Document Type: Article

References (29)

1. Global illicit drug trends 2003 (2003), United Nations Office on Drugs and Crime, New York
2. Illicit drug use in South Australia 2002. a statistical overview (2002), Drug & Alcohol Services Council, Adelaide
3. Doran C.M., Shanahan M., Mattick R.P., Ali R., White J., and Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 71 (2003) 292-302
4. Statistics on drug use in Australia 2004 (2005), Australian Institute of Health and Welfare, Canberra
5. Bell J., Burrell T., Indig D., and Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend 81 (2006) 55-61
6. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25 (2005) 193-200
7. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57 (2006) 119-137
8. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
9. Lin J.H., and Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35 (2003) 417-454
10. Callaghan R., and Riordan J.R. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268 (1993) 16059-16064
11. Bouer R., Barthe L., Philibert C., Tournaire C., Woodley J., and Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 13 (1999) 494-500
12. Thompson S.J., Koszdin K., and Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92 (2000) 1392-1399
13. Wang J.-S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., and DeVane C.L. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173 (2004) 132-138
14. Kreek M.J., Garfield J.W., Gutjahr C.L., and Giusti L.M. Rifampin-induced methadone withdrawal. N Engl J Med 294 (1976) 1104-1106
15. Eich-Hochli D., Oppliger R., Golay K.P., Baumann P., and Eap C.B. Methadone maintenance treatment and St. John's Wort-a case report. Pharmacopsychiatry 36 (2003) 35-37
16. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13 (2003) 481-494
17. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
18. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297 (2001) 1137-1143
19. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Med Genet 73 (2003) 1162-1169
20. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
21. Excoffier L., Laval G., and Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1 (2005) 47-50
22. Foster D.J.R., Somogyi A.A., White J.M., and Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57 (2004) 742-755
23. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
24. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
25. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15 (2005) 693-704
26. Crettol S., Deglon J.-J., Besson J., Croquette-Krokkar M., Gothuey I., Hammig R., et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78 (2005) 593-604
27. Foster D.J.R., Somogyi A.A., and Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47 (1999) 403-412
28. Kharasch E.D., Hoffer C., Whittington D., and Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition and miotic effects of methadone. Clin Pharmacol Ther 76 (2004) 250-269
29. Lötsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmoller J., et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79 (2006) 72-89